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A combined solid- and solution-phase approach 
provides convenient access to analogues of the 
calcium-dependent lipopeptide antibiotics 
Peter ‘t Harta,†, Laurens H. J. Kleijna,†, Gerjan de Bruinb, Sabine F. Oppedijka, 
Johan Kemminka, and Nathaniel I. Martina,*  
The calcium-dependent lipopeptide antibiotics represent a promising new class of 
antimicrobials for use in combatting drug-resistant bacteria. At present, daptomycin is the only 
such lipopeptide used clinically and displays potent antimicrobial activity against a number of 
pathogenic Gram-positive bacteria. Given the increasing need for new antibiotics, practical 
synthetic access to unnatural analogues of daptomycin and related antimicrobial lipopeptides is 
of value. We here report an efficient synthetic route combining solid- and solution-phase 
techniques that allows for the rapid preparation of daptomycin analogues. Using this approach, 
four such analogues, including two enantiomeric variants, were synthetized and their 
antimicrobial activities and hydrolytic stabilities evaluated. 
 
 
Introduction 
The accelerated appearance of antibiotic resistance presents a 
serious and growing global health risk. Despite the increasing 
need for new antibacterial agents, only two mechanistically and 
structurally new antibiotics have reached the clinic in the past 
40 years: linezolid and daptomycin.1,2 While linezolid is of 
synthetic origin, daptomycin (Figure 1) is a natural product 
isolated from fermentations of Streptomyces roseosporus. 
Daptomycin is rapidly bactericidal against Staphylococcus 
aureus, including methicillin-resistant S. aureus (MRSA), 
vancomycin-intermediate S. aureus (VISA) and vancomycin-
resistant S. aureus (VRSA) strains.3-5 Marketed under the trade 
name Cubicin, daptomycin is the first lipopeptide antibiotic of 
its kind to be approved for clinical use. Structurally unique, 
daptomycin is a cyclic depsipeptide composed of 13 amino 
acids (including non-proteinogenic and D-amino acids) and 
bears an N-terminal 10-carbon lipophilic tail. 
 While the precise mechanistic details of daptomycin’s 
antibacterial activity are unclear, it is known to disrupt aspects 
of bacterial cell membrane function.6,7 In this regard, the 
current model for daptomycin’s mode of action involves 
interaction with the bacterial membrane leading to rapid 
depolarization and a loss of membrane potential resulting in 
bacterial cell death without rupturing the cell.7 Daptomycin’s 
activity is calcium-dependent with serum levels of free calcium 
(45-55  µg/ml) sufficient to induce full antimicrobial activity.8 
Owing to the presence of four carboxylate side chains in the 
peptide, daptomycin is negatively charged at physiological pH 
and as such interacts with Ca2+ ions.9 Upon binding to Ca2+ 
daptomycin is believed to oligomerize after which it is able to 
effectively disrupt the cell membranes of sensitive bacteria 
leading to defective cell division and cell wall synthesis.6,7 
 Given its role as the prototypical calcium-dependent 
lipopeptide antibiotic, daptomycin has garnered much attention 
from the synthetic community.   Modified daptomycin 
analogues have been prepared via semi-synthesis10-13 and the 
synthesis of daptomycin itself has been achieved using both 
chemo-enzymatic approaches or total synthesis. The Marahiel 
group demonstrated that linear precursor peptide thioesters 
could be converted to their corresponding daptomycin 
macrocyles by action of the appropriate recombinant cyclase 
enzyme.14 In addition, the two total syntheses of daptomycin 
have also been reported to date.15,16 In both cases the synthetic 
routes described are labor intensive and make use of multi-step 
synthetic strategies. For these reasons we were drawn towards 
developing a convenient synthetic route for the preparation of 
daptomycin analogues so as to provide more rapid access to 
structurally diverse derivatives of this important antibiotic.  
Figure 1. Structure of daptomycin (1) with non-proteinogenic and 
D-amino acids indicated. 
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Results and Discussion 
In designing the daptomycin analogues to be prepared (Scheme 
1) we opted to replace the L-threonine residue at position 4 with 
L-diaminopropionic acid. In doing so we were able to 
circumvent incorporation of the synthetically challenging15,16 
ester linkage between Thr4 and Kyn13 found in the natural 
daptomycin macrocycle by replacing it with the more 
accessible amide linkage. In this regard, we also speculated that 
the corresponding macrocyclic amide analogue of daptomycin 
might show improved hydrolytic stability (vide infra). Aside 
from the amide for ester modification, we also incorporated L-
glutamic acid at position 12 in place of the (2S,3R)-3-methyl 
glutamate normally found in daptomycin. While published 
preparations of (2S,3R)-3-methyl glutamate are available,15-17 
they are rather lengthy (>10 steps) and time consuming.  In 
addition, Marahiel and coworkers previously investigated the 
same Glu for 3-MeGlu substitution in their chemo-enzymatic 
approach to daptoymcin analogues and found it to have a 
relatively small effect on antimicrobial activity (MIC values 
increased by ca. 7-fold).14 
 A variety of synthetic approaches were considered and 
explored in developing the route towards the daptomycin 
analogue illustrated in Scheme 1. Initial attempts at performing 
the entire synthesis on the solid phase by attachment to the 
resin via either of the aspartate side chains present in the 
macrocycle were unsuccessful and led us to explore the 
combined solid- and solution-phase approach indicated. To 
avoid any racemization in the later cyclization step, the peptide 
synthesis began at the glycine residue corresponding to position 
5 in daptomycin. Employing an acid sensitive resin (2-
chlorotrityl) and using standard SPPS techniques, the N-
terminus of the peptide was first installed, including the C10 
fatty acid tail. At this point, the diaminopropionic acid side 
chain was deprotected providing an attachment point for the 
kynurenine residue (position 13) after which the remainder of 
the peptide was assembled without incident. Of particular note 
was the need to incorporate a rare Fmoc-Kyn building block 
which was obtained via a recently described methodology for 
the gram-scale production of kynurenine in either L- or D- 
stereochemistry.18 In addition, DMB-protected glycine was 
introduced at position 10 to avoid aspartamide formation with 
the neighboring Asp residue. Upon completion, the 
intermediate protected peptide was cleaved from the resin using 
mild acid conditions and dissolved in CH2Cl2 at high dilution 
(0.5 mM) followed by treatment with BOP/DIPEA which led to 
clean formation of the desired macrocycle (Scheme 1). 
Following deprotection and purification by RP-HPLC, 
daptomycin analogue 2 was obtained. 
 Based upon the concise route developed for the preparation 
of daptomycin analogue 2, a second analogue, compound 3, 
was also prepared wherein L-kynurenine at position 13 was 
replaced by the structurally similar L-tryptophan. The synthesis 
of 3 proceeded without incident after which the antimicrobial 
activity of analogues 2 and 3 was compared with that of 
authentic daptomycin (Table 1). Using a standard broth dilution 
assay employing S. aureus (ATCC 29213) as an indicator 
strain, analogues 2 and 3 were both found to exhibit calcium-
dependent antimicrobial activity albeit at a significantly 
reduced level relative to that of daptomycin. The approximate 
100-fold decrease in activity was somewhat expected given the 
structural modifications introduced in analogues 2 and 3. 
Marahiel and coworkers reported similarly attenuated activities 
for daptomycin analogues obtained via their chemo-enzymatic 
approach.14 
 It is clear that replacement of the ester linkage in 
daptomycin with an amide dramatically alters antimicrobial 
activity. This effect may be due to conformational 
changes/restrictions in the macrocycle that result from 
incorporation of the amide. The amide for ester substitution is 
also expected to impart greater hydrolytic stability. Thus, the 
serum stability of analogues 2 and 3 was also evaluated and 
compared with that of daptomycin. Each peptide was incubated 
with human plasma serum at 37°C and sampled at specific time 
points. Under these conditions, daptomycin itself underwent 
significant degradation with an approximate 50% loss in the 
first 24 hours (Figure 2). This degradation is presumably due to 
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Reagents and conditions: a) Fmoc-Xaa-OH (or decanoic acid), 
BOP, DIPEA, DMF; b) Pd(PPh3)4, PhSiH3, CH2Cl2; c) Fmoc-Xaa-
OH, BOP, DIPEA, DMF; d) HFIP/CH2Cl2; e) BOP, DIPEA, 
CH2Cl2, 40 h; f) TFA/TIS/H2O. Highlighted in blue are the 
structural differences between compound 2 and daptomycin 
Scheme 1. Synthetic route developed for the preparation of 
daptomycin analogue 2. 
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hydrolytic opening of the macrocyclic lactone as evidenced by 
the appearance of a new M+H2O species. By comparison, 
amide analogues 2 and 3 were much more stable under the 
same conditions with only minimal degradation detected over 
extended time periods of up to 48 hours. 
 The relative ease with which analogues 2 and 3 where 
assembled prompted us to also prepare the corresponding 
enantiomeric analogues ent-2 and ent-3. The preparation of 
biologically active peptides in both enantiomeric forms is an 
established approach used in establishing the role of chiral 
biomolecular targets.19-22 If as some have proposed, daptomycin 
kills bacteria via membrane disruption without invoking a 
specific chiral bacterial target biomolecule, one would expect 
the “mirror-image” enantiomeric form of daptomycin to show 
an equal antibiotic activity. Conversely, should the 
enantiomeric form of daptomycin not show antibacterial 
activity, it can be taken as an indication that a chiral interaction 
with a specific biomolecular target is integral to daptomycin’s 
mode of action. To this end the enantiomeric analogues ent-2 
and ent-3 were assembled using the appropriate 
stereochemically-inverted amino acid building blocks. As 
expected, the enantiomeric analogues were shown to have 
identical retention times by analytical RP-HPLC (Figure 3) and 
exhibited optical rotations of equal magnitude but opposite 
sign. In addition, the circular dichroism spectra obtained for the 
daptomycin analogues further supported their enantiomeric 
nature (Supplemental Figure S3). 
 The antibacterial activities of ent-2 and ent-3 were next 
evaluated using the same assay as described above and revealed 
no detectable activity for both enantiomeric analogues (Table 
1). These results indicate that a specific chiral interaction(s) is 
required for the activity of those analogues bearing the “native” 
daptomycin stereochemistry and may also support a similarly 
stereospecific mode of action for daptomycin itself. Plausible 
candidates for the requisite chiral target could include any 
number of membrane proteins or chiral phospholipids. In this 
regard, recent reports suggest that phosphatidylglycerol may 
play a role. Specifically, in daptomycin-resistant strains of 
enterococci and S. aureus levels of phosphatidylglycerol are 
significantly reduced.23 
 
Conclusions 
In summary, we have developed a convenient approach 
employing both solid- and solution phase techniques for the 
preparation of analogues of the calcium-dependent lipopeptide 
family of antibiotics. While the antibacterial activity of the 
synthetic analogues was significantly reduced relative to that of 
daptomycin, their hydrolytic stability was greatly increased. 
The synthetic route here described should also be readily 
amenable to the production of new lipopeptide analogues with 
enhanced properties. Future work will be aimed at evaluating 
the effect of incorporating different amino acids in an attempt 
to increase antibacterial activity while maintaining the 
hydrolytic stability of these analogues. Support for this 
approach is evidenced by the observation that a tryptophan-for-
kynurenine substitution as in compound 3 results to a more 
active analogue. In addition, our findings with the enantiomeric 
analogues implicate the involvement of a specific chiral target 
biomolecule(s) in bacterial strains that are sensitive to 
daptomycin.  
Table 1. Antimicrobial activity of daptomycin analogues 
against S. aureus (ATCC 29123) 
Compound MIC (µM)a 
1 (Daptomycin) 1.23 
2 201.2 
3 100.8 
ent-2 not activeb 
ent-3 not activeb 
aCulture broth supplemented with Ca2+ (50 mg/L). 
bNot active at the highest concentration tested = 804 µM. 
	  
Figure 2. Serum stability of authentic daptomycin 1 (A) compared 
with analogues 2 (B) and 3 (C). Significant degradation of 
daptomycin is observed upon incubation at 37 °C while amide 
analogues 2 and 3 display increased stability. 
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Experimental  
Reagents and General Methods. All reagents employed were 
of American Chemical Society (ACS) grade or finer and were 
used without further purification unless otherwise stated. Both 
L-and D-kynurenine were synthesized according to a previously 
described procedure18 and converted into the requisite Fmoc-
building blocks based on established protocols.14 A large scale 
preparation of Fmoc-(Dmb)Gly-OH was also developed based 
on existing literature procedures (see supporting information 
for details).24, 25 All known compounds prepared had NMR 
spectra, mass spectra, and optical rotation values consistent 
with the assigned structures. Orthogonally protected Fmoc-L-
Dap(Aloc)-OH and Fmoc-D-Dap(Aloc)-OH were obtained from 
Iris Biotech GmbH. All reagents employed were of American 
Chemical Society (ACS) grade or finer and were used without 
further purification unless otherwise stated. All reactions and 
fractions from column chromatography were monitored by thin 
layer chromatography (TLC) using plates with a UV 
fluorescent indicator (normal SiO2, Merck 60 F254). One or 
more of the following methods were used for visualization: UV 
absorption by fluorescence quenching; iodine staining; 
phosphomolybdic acid:ceric sulfate:sulfuric acid:H2O (10 
g:1.25 g:12 mL:238 mL) spray; and ninhydrin staining. Flash 
chromatography was performed using Merck type 60, 230-400 
mesh silica gel. 
 
Instrumentation for Compound Characterization. NMR 
spectra were recorded at 300 or 500 MHz with chemical shifts 
reported in parts per million (ppm) downfield relative to 
tetramethylsilane (TMS). 1H NMR data are reported in the 
following order: multiplicity (s, singlet; d, doublet; t, triplet; q, 
quartet; qn, quintet and m, multiplet), number of protons, 
coupling constant (J) in Hertz (Hz) and assignment. When 
appropriate, the multiplicity is preceded by br, indicating that 
the signal was broad. 13C NMR spectra were recorded at 75.5 
MHz with chemical shifts reported relative to CDCl3 δ 77.0. 2D 
NMR experiments (TOCSY and HSQC) were performed on a 
500 MHz instrument. High-resolution mass spectrometry 
(HRMS) analysis was performed using an ESI instrument. 
Circular dichroism spectra were recorded on a Jasco J-810 CD-
spectrometer using a 2 mm cuvet. 
 
Peptide Synthesis. Lipopetide analogue 2 was synthesized 
beginning with Fmoc-Gly loaded 2-chlorotrityl resin (410 mg, 
0.25 mmol). Fmoc groups were removed with 20% piperidine 
in DMF (10 mL, 1x1 min., 1x30 min.). Coupling reactions were 
done in DMF (10 mL) with 4 equivalents of Fmoc-amino acid 
(or capric acid), 4 equivalents of BOP and 8 equivalents of 
DIPEA (1 hour). For removal of the Aloc protecting group, the 
resin was first washed with CH2Cl2 (2x10 mL) under argon 
after which PhSiH3 (0.74 mL, 6.0 mmol) in CH2Cl2 (4 mL) and 
Pd(PPh3)4 (74 mg, 0.06 mmol) in CH2Cl2 (12 mL) were added 
and the mixture swirled under argon for 1 hour. The reaction 
mixture was drained and the procedure was repeated. To 
remove residual palladium catalyst, the resin was then washed 
with CH2Cl2 (5x10 mL), a 0.5% solution of 
diethyldithiocarbamic acid trihydrate sodium salt in DMF 
(5x10 mL), and DMF (5x10 mL). After Aloc removal, the 
Figure 3. Overlays of analytical RP-HPLC traces obtained for enantiomeric daptomycin analogues A) 2 and ent-
2 and B) 3 and ent-3. 
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remainder of the peptide was assembled on resin using standard 
SPPS approaches. The protected peptide was cleaved from the 
resin by addition of hexafluoroisopropanol (HFIP) in CH2Cl2 
(1:4, 6 mL, 1 hour) and the filtrate collected. The resin was 
rinsed with additional HFIP/CH2Cl2 (2x3 mL) and the 
combined filtrates concentrated under vacuum. The crude linear 
peptide was dissolved in CH2Cl2 (500 ml, approximate peptide 
concentration of 0.5 mM ) and BOP (0.22 g, 0.50 mmol, 2.0 
equiv) and DIPEA (0.17 mL, 1.0 mmol, 4.0 equiv) were added. 
The cyclization reaction was monitored by TLC (5% MeOH in 
CH2Cl2) and was typically complete within 24 to 40 h.  The 
reaction mixture was then concentrated, dissolved in EtOAc 
(250 mL) and washed with 1M KHSO4 (2x200 mL) followed 
by saturated NaHCO3 (2x200 mL). The organic layer was dried 
over Na2SO4, filtered and concentrated under vacuum. The 
protected cyclic peptide was treated with a solution of 
TFA/TIS/H2O (95:2.5:2.5, 10 ml) for 1.5 hours. The mixture 
was then added to cold ether and the precipitated peptide 
collected by centrifugation and further was washed with cold 
ether (2x). Crude peptides were purified by RP-HPLC using a 
Maisch ReproSil-Pur C18-AQ column (250 x 22 mm, 10µm) 
and employing a gradient of 30% to 70% Buffer B with a flow 
of 12 ml/min (Buffer A: 95% H2O, 5% MeCN, 0.1% TFA; 
Buffer B: 5% H2O, 95% MeCN, 0.1% TFA). Product 
containing fractions were pooled and lyophilized to yield 
between 5-10 mg of pure peptide (1.2-2.4% overall yield). 
Table 1 summarizes the analytical data obtained for the four 
daptomycin analogues prepared as well as for authentic 
daptomycin. 
 
Biological activity assays. The daptomycin analogues were 
tested against S. aureus (ATCC 29213) as an indicator strain. 
Two-fold serial dilutions of each compound were made in 
microtiter plates using Mueller-Hinton broth. After incubation 
at 37°C for 16 h, MIC values were determined visually. In these 
assays calcium- and magnesium-free Mueller-Hinton broth 
(Fluka) was supplemented with CaCl2 (final Ca2+ concentration 
50 mg/L) and with MgCl2  (final Mg2+ concentration 10 mg/L) 
or alternatively with MgCl2 alone to assess the effect of calcium 
on antibacterial activity.  
 
Serum stability assays. Daptomycin and analogues 2 and 3 
were added to human plasma serum to a final concentration of 
150 µg/ml, followed by incubation at 37°C. At 0, 24 and 48 
hours a 100 µl aliquot was taken and added to a 200 µl volume 
of methanol to precipitate plasma proteins (methanol also 
contained 0.075 mg/ml ethylparaben as an internal standard). 
The mixture was vortexed for 5 seconds and allowed to stand at 
room temperature for 15 minutes. After centrifugation at 13000 
rpm for 5 minutes, the supernatant was removed and used for 
HPLC analysis. Analysis of the samples was performed by 
analytical RP-HPLC with a Maisch ReproSil-Pur 120 C18-AQ 
column (250 x 4.6 mm, 5µm) and a linear gradient of 0-100% 
buffer B over 48 minutes at a flow rate of 1ml/min (Buffer A: 
95% H2O, 5% MeCN, 0.1% TFA; Buffer B: 5% H2O, 95% 
MeCN, 0.1% TFA). Both the internal standard and peptides 
were detected at 220 nm allowing for the amount of intact 
peptide to be calculated based upon the ratio of peak areas 
corresponding to the internal standard and the intact peptides. 
 
Circular dichroism spectroscopy. A 60 µM solution of each 
peptide was prepared by dissolving them in a 20 mM HEPES 
buffer (pH 7.4). Samples were measured at room temperature 
from 210-250 nm at a scan rate of 20 nm/min and a bandwidth 
of 0.1 nm. The spectra were converted to molar ellipticities in 
units of deg x cm2/dmol. 
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